CD38

CD38 inhibitor 1 is a potent CD38 inhibitor that is effective against human CD38 (IC50 value is 7.3 nM) and mouse CD38 (IC50 value is 1.9 nM).

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma. It exhibits antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, directly inducing apoptosis without crosslinking. Isatuximab inhibits CD38 extracellular enzyme activity, affecting various cellular functions.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Kuromanin chloride (Chrysontemin chloride) is potent antioxidants and free radical scavengers, may act as modulators of gene regulation and signal transduction pathways.

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

Luteolinidin chloride is a natural product. It is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.

Mezagitamab (TAK-079) is a fully humanized IgG1λ monoclonal antibody against CD38 with high affinity for CD38-expressing cells (including plasma mother cells, plasma cells, and natural killer cells), which depletes CD38-expressing tumor cells through antibody- and complement-dependent cytotoxicity Mezagitamab may be used in the study of recurrent/refractory multiple myeloma (RRMM), which is the most common form of cancer. multiple myeloma (RRMM) and primary thrombocytopenic purpura (ITP).

RBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.

MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury.

SAR442257 is a humanized IgG4-S228P (κ type) monoclonal antibody designed to target CD38 on the surface of multiple myeloma cells, while also co-stimulating CD3 and CD28 molecules on T cells.

Ara-F-NAD+, an arabino analogue of NAD + , is a potent, slow-binding CD38 NADase inhibitor, with a K i of 169 nM.

CD38 inhibitor 2 is a potent CD38 inhibitor (IC 50 = 0.01 ~ 0.1 μΜ).

Ara-F-NAD+ sodium, an arabino analogue of NAD+, serves as a potent, reversible, and slow-binding inhibitor of the CD38 NADase [1] [2].

6-Alkyne-F-araNAD is an irreversible CD38 inhibitor that aids in better visualization of intracellular CD38 localization when used alongside other fluorescent probes (such as SR101−F-araNMN).

AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 and CD3E. It effectively kills cancer cells that express CD38, stimulates T cell proliferation, and reduces cytokine release. AMG-424 exhibits antitumor activity in mouse cancer models with bone marrow invasion and induces peripheral B cell depletion in cynomolgus monkeys. It is used in studies of multiple myeloma. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3.

Erzotabart, an IgG1-kappa monoclonal antibody targeting CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) in Homo sapiens, exhibits antineoplastic activity [1].

CD38 Inhibitor 3 (compound 1), with an IC50 of 11 nM, is a potent agent that enhances mitochondrial biogenesis, diminishes lactate levels, and augments both NAD+ content and Nrf2 expression. In a Pus1 -/- mouse model of mitochondrial myopathy, it also elevates muscle function and bolstering exercise capacity [1].

Noraramtide (BHV-1100) is an antibody recruiting molecule that specifically binds to the CD38 molecule to recruit natural killer (NK) cells. This interaction enhances the NK cells' ability to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while preventing mutual NK cell destruction. Noraramtide is utilized in research on autologous cancer immunotherapy.

Modakafusp alfa (TAK-573) is a humanized anti-CD38 IgG4 monoclonal antibody fused with 2 attenuated IFNα2b molecules, being researched for potential use in treating multiple myeloma [1].

Lumrotatug is a human-derived IgG1κ monoclonal antibody designed to target CD38. The isotype control for Lumrotatug is HumanIgG1kappa, Isotype Control.